Victory Capital Management
ADIL

Victory Capital Management’s Adial Pharmaceuticals ADIL Stock Holding History

Victory Capital Management’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5
Closed -$4K – 2511
2020
Q1 		$4K Buy
+5
New +$5.34K ﹤0.01% 3504
2019
Q4 		– Sell
-2
Closed -$2K – 2636
2019
Q3 		$2K Buy
+2
New +$2.13K ﹤0.01% 3612

Other funds holding ADIL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Victory Capital Management's ADIL Position: Q2 2020 in Review

Victory Capital Management sold out of Adial Pharmaceuticals (ADIL) in Q2 2020, closing a stake of 5 shares — an estimated $4K sold.

Victory Capital Management first reported a position in ADIL in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2020. 10 funds tracked by Wall St. Rank hold ADIL as of Q2 2020.

  • Victory Capital Management reported no remaining Adial Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 5 Adial Pharmaceuticals shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in Adial Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Adial Pharmaceuticals position peaked at $4K in Q1 2020.
  • 10 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.